title: [Treatment of hypertension with a fixed combination of bopindolol and chlorthalidone (Sandoretic)].
abstract: A multicentric, prospective, 16-week open study evaluated the effectivity and tolerance of the fixed combination of the beta-blocking agent bopindolol with the diuretic chlorthalidone--Sandoretic in 81 patients with mild to moderate hypertension. The combination of these two drugs is appropriate, since both drugs have long-term effects. Sandoretic induced a decrease of the mean sitting initial systolic blood pressure of 162.5 +/- 16.5 mmHg to 134.2 +/- 12.8 mmHg at the end of the study, a decrease of 28.3 mmHg. Diastolic blood pressure decreased after 16 weeks of treatment from the initial value of 103.9 +/- 4.9 mmHg to 85.3 +/- 6.0, a decrease of 18.6 mmHg. Changes of the standing systolic and diastolic blood pressures were of similar magnitude. Sandoretic treatment led to a normalization of the diastolic blood pressure (90 mmHg and lower) in 80.3% of patients. In 49.4% of patients treatment with Sandoretic led even to a diastolic blood pressure of 85 mmHg and lower and 29.6% patients had at the end of treatment diastolic blood pressure 80 mmHg and lower. Tolerance of the drug was excellent in 75.3% patients. Sandoretic induced a mild, however, significant decrease of potassium plasma levels. The increase of the uric acid plasma level was also significant. Monitoring of potassium plasma levels is therefore necessary during the treatment with Sandoretic. In patients showing a decrease of the potassium plasma level, potassium sparing diuretic-amiloride should be added or the dosage of the drug should be halved.
authors.affiliation: Klinika kardiologie IPVZ, Praha.
authors.forename: J
authors.initials: J
authors.lastname: Widimský
authors.forename: V
authors.initials: V
authors.lastname: Lánská
authors.forename: V
authors.initials: V
authors.lastname: Hulínský
authors.forename: I
authors.initials: I
authors.lastname: Balazovjech
authors.forename: V
authors.initials: V
authors.lastname: Havlík
authors.forename: P
authors.initials: P
authors.lastname: Havránek
authors.forename: E
authors.initials: E
authors.lastname: Kroupa
authors.forename: L
authors.initials: L
authors.lastname: Nikodýmová
authors.forename: F
authors.initials: F
authors.lastname: Pátek
authors.forename: F
authors.initials: F
authors.lastname: Svítil
authors.forename: P
authors.initials: P
authors.lastname: Svihovcová
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001794:Blood Pressure / Q000187:drug effects; D002752:Chlorthalidone / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D011446:Prospective Studies
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D004338:Drug Combinations; D010869:Pindolol; C036007:bopindolol; D002752:Chlorthalidone
vernacular_title: Lécba hypertenze fixní kombinací bopindololu a chlorthalidonu (Sandoretic).